Structure Therapeutics(GPCR.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Structure Therapeutics
GPCR.US
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation.
4.896 T
GPCR.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It

    Structure Therapeutics CEO Ray Stevens outlined the company's strategy for its oral GLP-1 weight-loss drug, aleniglipron, at the JPMorgan Healthcare Conference. With plans to advance into Phase 3 trials, Stevens highlighted the drug's efficacy, tolerability, and potential for combination therapies. He noted that aleniglipron has shown significant weight loss results and can be produced efficiently. However, he expressed concerns about unapproved alternatives affecting market entry. Structure's shares saw a rise following positive Phase 2 data, trading near a 52-week high.

    benzinga_article·
    US
    PBE
    -1.52%
    US
    FBT
    -1.17%
    US
    BBH
    -0.45%
    benzinga_article·
    US
    PBE
    -1.52%
    US
    FBT
    -1.17%
    US
    BBH
    -0.45%

    Exicure Achieves Milestone in Collaboration with GPCR Therapeutics

    Exicure Inc. has reached a milestone in its collaboration with GPCR Therapeutics Inc. by completing a Phase 2 clinical trial for its stem cell mobilizer. This achievement triggers a $1 million milestone payment to GPCR and activates a sublicensing income-sharing agreement. The collaboration centers on Burixafor (GPC-100), a small molecule CXCR4 inhibitor.

    Reuters·
    US
    BBH
    -0.45%
    US
    SBIO
    -3.01%
    US
    ARKG
    -4.70%
    Reuters·
    US
    BBH
    -0.45%
    US
    SBIO
    -3.01%
    US
    ARKG
    -4.70%

    Assessing Structure Therapeutics (GPCR) Valuation After Genentech Deal And Growing Obesity Pipeline Confidence

    Structure Therapeutics (GPCR) is gaining investor interest following a licensing deal with Genentech worth US$100 million and positive developments in its obesity pipeline. The company's stock has seen significant price momentum, with a 7-day return of 16.81% and a 90-day return of 241.41%. Currently trading at US$91.02, GPCR has a price-to-book ratio of 8.2x, which is favorable compared to peers but high against the broader pharmaceutical sector. Analysts are optimistic about upcoming clinical milestones, although risks remain if trial outcomes are unfavorable.

    Simplywall·
    US
    PBE
    -1.52%
    US
    FBT
    -1.17%
    US
    SBIO
    -3.01%
    Simplywall·
    US
    PBE
    -1.52%
    US
    FBT
    -1.17%
    US
    SBIO
    -3.01%

    Structure Therapeutics shares are trading higher after Guggenheim raised its price target on the stock from $90 to $140.

    benzinga_article·
    US
    XBI
    -2.68%
    US
    BIB
    -2.77%
    US
    SBIO
    -3.01%
    benzinga_article·
    US
    XBI
    -2.68%
    US
    BIB
    -2.77%
    US
    SBIO
    -3.01%

    Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments

    Structure Therapeutics CEO Raymond Stevens warns that compounded weight-loss drugs pose a significant threat to new obesity treatments, including their experimental pill aleniglipron. As the company prepares for approval, Stevens highlights the challenge of unapproved alternatives that could undermine market entry. Despite easing supply constraints, compounded drugs remain popular due to lower costs. While aleniglipron's complex manufacturing may offer some protection, industry leaders agree that regulatory oversight is insufficient to control compounded drug production. Structure Therapeutics shares fell 0.80% to $83.65 amid these concerns.

    benzinga_article·
    US
    GPCR
    -1.63%
    benzinga_article·
    US
    GPCR
    -1.63%
    © 2026 Longbridge｜Disclaimer